MorphoSys AG
FRA:MOR ISIN:DE0006632003
MorphoSys is a publicly traded biotechnology company focused on the generation of fully human antibodies as a means to discover and develop innovative antibody-based drugs against life-threatening diseases. MorphoSys's goal is to establish HuCAL as the technology of choice for antibody generation in research, diagnostics and therapeutic applications. The Company currently has therapeutic and research alliances with the majority of the world's largest pharmaceutical companies including Bayer-Schering, Boehringer Ingelheim, Centocor/Johnson & Johnson, Novartis, Pfizer and Roche. Within these partnerships, more than 40 therapeutic antibody programs are ongoing in which MorphoSys participates through exclusive license and milestones payments as well as royalties on any end products. Additionally, MorphoSys is active in the antibody research market through its AbD Serotec business unit. The business unit has operations in Germany (Munich), the U.S. (Raleigh, NC) and U.K. (Oxford).
News
MorphoSys AG (FRA:MOR) MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and Wacker Chemie AG are intensifying their cooperation in the use of WACKER's prokaryotic secretion technology. The two companies have signed a new agreement precisely defining areas of use and production limits under which MorphoSys will continue to use the secretion system on a research scale. As a result, MorphoSys will now be able to use the WACKER technology for both the early development phase of therapeutic projects as well as the production of diagnostic and research antibodies. If the agreed quantity limits are exceeded at MorphoSys, WACKER is able to provide a seamless transition to large-scale manufacturing services.
MorphoSys AG (MUC:MOR) Antibody Shows Ability to Inhibit Disease in an Established RA Model
MorphoSys AG (MUC:MOR) MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its management will give company presentations at two investor conferences in November 2008.
MorphoSys AG (MUC:MOR) Full Year Profit Guidance Increased
MorphoSys AG (MUC:MOR) MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its first nine months' 2008 results on October 30, 2008 at 7:30 a.m. CET.
MorphoSys AG (MUC:MOR) MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that Shionogi & Co., Ltd., Osaka, Japan, has elected to extend its current license agreement covering the use of MorphoSys's HuCAL technology in drug discovery, for three additional years. Under the terms of the agreement, Shionogi will continue to have the right to use MorphoSys's proprietary antibody library HuCAL GOLD for research purposes at one of its research sites. MorphoSys will receive annual user fees from Shionogi for access to the HuCAL technology. Further financial details were not disclosed.
MorphoSys AG (MUC:MOR) MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that it has exercised its first option to participate in the development of a therapeutic antibody program within its collaboration with Novartis. In a first, pre-development step, Novartis will fund the companies' joint efforts until the program reaches formal pre-clinical development. MorphoSys will recognize its share of the funding as additional revenues.
MorphoSys AG (MUC:MOR) MOR103 anti-GM-CSF Antibody Shows Subpicomolar Affinity for its Target Molecule
MorphoSys AG (MUC:MOR) MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its management will give company presentations at five investor conferences in September 2008.
MorphoSys AG (PINKSHEETS:MPHSF) Revenues up 16 %, Operating Profit More Than Doubled
###
5,106 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 6) (Last 30 Days: 52) (Since Published: 5106)
